Omideon

Executive Summary

Omideon is a UK-based preclinical biotechnology company pioneering a novel therapeutic modality targeting the tumour glycome using carbohydrate-binding molecules (CBMs). Its lead candidate, OMI-DG1, is a first-in-class multivalent CBM being developed for ovarian and colorectal cancers. The company’s approach exploits the differential glycosylation patterns on cancer cells, offering a potentially selective and potent treatment with reduced off-target effects. Founded in 2020, Omideon has not yet disclosed funding rounds or valuation but is listed on biopharmguy directories, indicating early-stage interest. The glycome targeting field is nascent but gaining traction, and if Omideon’s platform validates, it could position the company as a leader in this niche. However, as a preclinical entity with no disclosed partnerships or regulatory milestones, the risk profile is high. The executive summary highlights the scientific rationale and market potential while acknowledging the early stage and lack of disclosed financial or operational data.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for OMI-DG1 in ovarian cancer models30% success
• Q2 2026Series A financing or grant award to advance IND-enabling studies50% success